Results 161 to 170 of about 5,082,017 (204)

Combination of Antibiotic Treatment with the Thrombin Inhibitor Recombinant Hirudin for the Therapy of Experimental Klebsiella pneumoniae Sepsis

Thrombosis and Haemostasis, 1994
SummaryRats which were infected with the gramnegative pathogen Klebsiella pneumoniae develop disseminated intravascular coagulation (DIC), multi-organ failure (MOF) and finally die in a septic shock. We investigated the therapeutic effect of antibiotic (tobramycin) treatment combined with the infusion of the highly specific thrombin inhibitor rec ...
G, Dickneite, J, Czech
openaire   +3 more sources

Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus?

Circulation, 1996
Background Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system.
J S, Mruk, P, Zoldhelyi, M W, Webster, M, Heras, D E, Grill, D R, Holmes, V, Fuster, J H, Chesebro   +7 more
openaire   +3 more sources

Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK) Interim results

European Heart Journal, 1995
To evaluate the efficacy and safety of hirudin, a direct thrombin inhibitor, in patients with acute myocardial infarction, a dose-finding, angiography study was carried out. After a pilot phase in 10 patients treated with a bolus of 0.1 mg.kg-1 and a continuous infusion of 0.06 mg.kg-1.h-1 (dose group I), two doses of hirudin, bolus 0.2 mg.kg-1.h-1 (DG
G P, Molhoek, G J, Laarman, D J, Lok, C M, Luz, J H, Kingma, A A, Van den Bos, P, Zijnen, A H, Bosma, D P, Hertzberger, L H, Takens   +9 more
openaire   +3 more sources

Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis

American Journal of Hematology, 1993
S. Nand
openaire   +3 more sources

Frequency of “optimal anticoagulation” for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW O23)

The American Journal of Cardiology, 1995
Abstract This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 ma/kg/hour over 48 hours ...
Uwe Zeymer, Rainer von Essen, Ulrich Tebbe, Walter Niederer, Wolfgang Mäurer, Albrecht Vogt, Karl-Ludwig Neuhaus   +6 more
openaire   +2 more sources

Aptamer-thrombin loaded magnetic microspheres for bio-specific extraction and precise detection of hirudin.

Talanta: The International Journal of Pure and Applied Analytical Chemistry, 2023
Hirudin, that is naturally occurring in leeches (Hirudo medicinalis) and known as the most potent natural inhibitor of thrombin, exerts double-edged effects in clinic application.
Xiujun Cao, Yuan Luo, Xueli Liu, Chunqing Shang, Jun Lu, Guoxin Song, Chunhui Deng   +6 more
semanticscholar   +1 more source

Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation.

Small, 2022
Due to the high recurrence rate and mortality of venous thrombosis, there is an urgent need for research on antithrombotic strategies. Because of the short half-life, poor targeting capabilities, bleeding complications, and neurotoxic effects of ...
Shuting Li, Kai Zhang, Zhaoyu Ma, Weiyun Zhang, Zhiyong Song, Wenjing Wang, Heyou Han   +6 more
semanticscholar   +1 more source

Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein.

Thrombosis Research, 2021
A pure recombinant staphylokinase-hirudin fusion protein (SFH) was obtained by recombinant genetic engineering and purification techniques. The thrombolytic and anticoagulant activities of SFH were investigated using in vitro coagulation models and ...
Keyun Ren, Hao Gong, Junjie Huang, Yubin Liu, Qiaoyan Dong, Kun He, Lvming Tian, Fan Zhang, Aiping Yu, Chutse Wu   +9 more
semanticscholar   +1 more source

Novel Strategy of Gene Delivery System Based on Dendrimer Loaded Recombinant Hirudine Plasmid for Thrombus Targeting Therapy

Molecular Pharmaceutics, 2019
This study proposed a new nonviral gene delivery system for thrombus targeting therapy based on PEGlyation polyamides dendrimer (PAMAM) modified with RGDyC to condense the pDNA with recombinant hirudine (rHV) gene (RGDyC-rHV-EGFP). The RGDyC-mPEG-PAMAM was synthesized and characterized by 1H NMR, PAMAM/pDNA was characterized by particle size, zeta ...
Junjie Chen, Yanping Lu, Ying Cheng, Rui Ma, Jiafeng Zou, Hongyue Zheng, Ruwei Wang, Zhihong Zhu, Fanzhu Li   +8 more
openaire   +2 more sources

Leech bionic Hirudin fusion protein prodrug loaded microneedles for long-term inhibition of thrombosis.

Journal of Controlled Release
The clinical use of anticoagulant drugs for thrombosis is limited by short half-life and bleeding risk, requiring frequent administration and close monitoring.
Xue Tian, Shuo Su, Yuhang Wu, Hao Zhang, Bingfang He, Bingbing Gao, Tianyue Jiang   +6 more
semanticscholar   +1 more source